Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells

Centeno, Christopher J.; Busse, Dan; Kisiday, John D.; Keohan, Cristin; Freeman, Michael; Karli, David C.

doi:10.1016/j.mehy.2008.06.042

Cited by 246 publications

(255 citation statements)

References 49 publications

Supporting

Mentioning

239

Contrasting

Unclassified

Order By: Relevance

“…The first experiment was reported by Centeno, in May 2008, on one human subject. 26,27 It showed good results at 6 months with no side-effects. We started our project in June 2008, as a pilot study, to see if MSCs were able to repair the cartilage of an OA joint, the safety and outcome at long follow-up.…”

Section: Discussionmentioning

confidence: 86%

“…Results at 6 months were improved visual analogue score (VAS) on pain, walking distance, and joint space width on magnetic resonance imaging (MRI). 26,27 The second human experience was in our group of four patients; two men and two women 28 with moderate to severe OA of both knees. They received 8-9 million autologous MSC in their worse knee.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

et al. 2015

View full text Add to dashboard Cite

Aim: Osteoarthritis is a degenerative joint disease characterized by the destruction of joint cartilage. Mesenchymal stem cells (MSCs) are found in low numbers in normal cartilage, mainly in the superficial layer, acting as repairing agents. In OA, MSCs are seen in larger numbers, but act chaotic and are unable to repair the cartilage. The synovial membrane becomes inflamed and interacts with the cartilage. Transplanted MSC have the ability to normalize them, redirecting them to their normal function. In a preliminary study, we showed that MSC could improve knee OA in four patients at 6 months. This report shows their long-term follow-up at 5 years.Methods: One patient was lost to follow-up at 2 years and three were followed for 5 years. They were aged 55, 57, 65 and 54 years, and had moderate to severe knee osteoarthritis. The worse knee of each patient was injected with 8-9 9 10 6 MSC.Results: As previously reported, all parameters improved in transplant knees at 6 months (walking time, stair climbing, gelling pain, patella crepitus, flection contracture and the visual analogue score on pain). Then, they started gradually to deteriorate, but at 5 years they were still better than at baseline. PGA (Patient Global Assessment) improved from baseline to 5 years. The better knee at baseline (no MSC), continued its progression toward aggravation and at 5 years became the worse knee. Conclusion:Transplant knees were all in a rather advanced stage of OA. Earlier transplantation may give better results in long-term follow-up. This is what future studies have to demonstrate.

show abstract

Section: Discussionmentioning

confidence: 86%

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

et al. 2015

View full text Add to dashboard Cite

show abstract

“…One approach to regenerative *Address correspondence to this author at the Caring Medical and Rehabilitation Services, 715 Lake St., Oak Park IL 60301 USA; Tel: 708-848-7789; Fax: 708-848-7763; E-mail: drhauser@caringmedical.com therapy is to supply affected joints with either autologous chondrocytes or chondrogenic bone marrow-derived mesenchymal stem cells (BMSCs), prepared as a buffy coat fraction of bone marrow with or without ex vivo expansion. Recent preliminary studies support the investigation of these therapies for OA [4][5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 91%

“…Thus, preclinical and clinical studies of the use of autologous bone marrow for musculoskeletal and bone tissue repair have focused on preparations in which MSCs are enriched and expanded, with the assumption that the quantity of delivered MSCs is critical [4,6,7,[26][27][28]. In this regard, new products have recently been developed and are currently making the claim that stem cells can be isolated and concentrated for point-ofcare usage; these products are known as bone marrow concentrate (BMC) systems.…”

Section: Introductionmentioning

confidence: 99%

Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy (Prolotherapy)

Hauser

Eteshola²

2013

TOSCJ

View full text Add to dashboard Cite

Adult mesenchymal stem cells (MSCs) obtainable from autologous bone marrow aspirates have generated tremendous interest in the medical and scientific communities in the last two decades and are currently being investigated by a of interested physicians for use in point-of-care stem cell therapies due to their great potential to differentiate into multiple cell lineages such as bone, cartilage, muscle, tendon, and nerve. However, as these stem cells are found in very low numbers in adult tissue, centrifugal concentration or expansion through in vitro culturing has been pursued to obtain higher numbers of efficacious regenerative therapeutic applications. More recently, some physicians and scientists have chosen to explore use for direct injection of un-fractionated, native whole bone marrow aspirate as a strategy in regenerative treatment regimes. This review examines the potential merits and disadvantages of using either concentrated and culture expanded MSCs versus native whole bone marrow aspirate as key proliferant in direct regenerative injection therapy (RIT). Results from a number of published investigations have clearly shown high potential of various deleterious effects on manipulating MSCs obtained from native bone marrow aspirate either by centrifugal forces or expansion through in vitro culturing; moreover, currently used centrifugal concentration techniques do not significantly concentrate MSCs from bone marrow aspirate, thus, defeating the purpose of this manipulative step. On the other hand, preliminary results and observations of using un-fractionated whole bone marrow injection for treatment of various musculoskeletal joint diseases (for example, osteoarthritic joints) suggest that the procedure is safe and potentially efficacious, with no known deleterious effects as yet reported.

show abstract

“…Limb regeneration is a multi step process related to developmental biology, regenerative medicine and tissue engineering [119]. Though, this property lacks in higher animals but fetuses own this property and show growth of limbs in normal course.…”

Section: Regeneration Of Limbs and Local Tissues In Invertebratesmentioning

confidence: 99%

Role of regeneration in tissue repairing and therapies

Upadhyay¹

2015

J Regen Med Tissue Eng

View full text Add to dashboard Cite

Present review article emphasizes role of regeneration mechanism in various tissues and its use in organ transplantation for wound healing and repairing. This article also explains uses of various stem cell types in transplantation technologies and its applications in regenerative medicine and therapeutics. This review also addresses tissue engineering methods and use of new biological scaffold materials and promising candidates such as immunomodulators, adhesions, integrins in tissue repairing and induction of regeneration in injured tissues. In addition, role of various molecules of immune cell system, gene cascades and transcription specific proteins (TSPs) and growth factors in formation of microenvironment for differentiation are also explained. Moreover, mechanism of regeneration in various tissues such as neural, skeletal, cardiac, muscular, adipose and gonadial tissues, and bone marrow is described in detail. This article also suggest an urgent need for development of new advanced methods, technologies, biomatrices, polymers and scaffold materials, and cell based therapies to overcome the problem of disable and injured patients. Hence, landmark innovations are required in the field of regenerative medicine, tissue engineering, and developmental biology for successful tissue repairing and organ transplants to serve the human society.

show abstract

Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells

Cited by 246 publications

References 49 publications

Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

Rationale for Using Direct Bone Marrow Aspirate as a Proliferant for Regenerative Injection Therapy (Prolotherapy)

Role of regeneration in tissue repairing and therapies

Contact Info

Product

Resources

About